These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11402608)

  • 1. [An example of interactions between SSRI preparations and tolterodine?].
    von Segebaden C
    Lakartidningen; 2001 May; 98(18):2234. PubMed ID: 11402608
    [No Abstract]   [Full Text] [Related]  

  • 2. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N; Forslund C; Hallén B; Gustafsson LL; Bertilsson L
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.
    Edwards KR; O'Connor JT
    J Am Geriatr Soc; 2002 Jun; 50(6):1165-6. PubMed ID: 12110086
    [No Abstract]   [Full Text] [Related]  

  • 5. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B; Serra DB
    Clin Pharmacol Ther; 2008 Feb; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
    Burger M
    Eur Urol; 2007 Nov; 52(5):1516-7. PubMed ID: 17574732
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Chapple C
    Urologe A; 2007 Apr; 46(4):422, 424-6; author reply 426, 428. PubMed ID: 17384923
    [No Abstract]   [Full Text] [Related]  

  • 9. Hallucinations with tolterodine.
    Williams SG; Staudenmeier J
    Psychiatr Serv; 2004 Nov; 55(11):1318-9. PubMed ID: 15534031
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
    Olsson B; Landgren BM
    Clin Ther; 2001 Nov; 23(11):1876-88. PubMed ID: 11768839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual hallucinations at the onset of tolterodine treatment in a patient with a high-level spinal cord injury.
    Malavaud B; Bagheri H; Senard JM; Sarramon JP
    BJU Int; 1999 Dec; 84(9):1109. PubMed ID: 10571650
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolterodine once-daily in treatment of the overactive bladder.
    Peters KM; Huang RR
    Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Goepel M
    Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity--a comment.
    Short DD
    Pharmacotherapy; 1999 Oct; 19(10):1188. PubMed ID: 10512072
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine-associated acute mixed liver injury.
    Schlienger RG; Keller MJ; Krähenbühl S
    Ann Pharmacother; 2002 May; 36(5):817-9. PubMed ID: 11978158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.